Chachques J C, Pellerin M
Department of Cardiovascular Surgery, Broussais Hospital, Paris, France.
Curr Opin Cardiol. 1994 Mar;9(2):186-90. doi: 10.1097/00001573-199403000-00008.
Surgical treatment of valvular heart disease is a field of constant clinical and experimental research. Recently, much attention has been devoted to the improvement of valve repair techniques. The physiopathology of the left ventricular outflow tract obstruction following mitral valve repair has become better understood. Surgical techniques to correct this infrequent complication have been developed. Conservative valvular surgery or homograft use are among the surgical treatments for infective endocarditis; innovative experimental and clinical studies on mitral and tricuspid homografts have provided interesting results. New biological valves have come into use; intraoperative creation of a cardiac bioprosthesis using glutaraldehyde-treated autologous pericardium is an attractive surgical innovation. Stentless bioprostheses are also under investigation, to evaluate their hemodynamic and clinical characteristics. The biology of bioprosthesis deterioration progresses at the cellular level, with the implication of phagocytosis as a contributing factor.
心脏瓣膜病的外科治疗是一个不断进行临床和实验研究的领域。最近，瓣膜修复技术的改进受到了广泛关注。二尖瓣修复术后左心室流出道梗阻的病理生理学已得到更好的理解。已开发出纠正这种罕见并发症的手术技术。保守性瓣膜手术或使用同种异体移植物是感染性心内膜炎的外科治疗方法之一；关于二尖瓣和三尖瓣同种异体移植物的创新性实验和临床研究取得了有趣的成果。新型生物瓣膜已投入使用；术中使用经戊二醛处理的自体心包制作心脏生物假体是一项有吸引力的外科创新。无支架生物假体也在研究中，以评估其血流动力学和临床特征。生物假体退化的生物学过程在细胞水平上进展，吞噬作用是一个促成因素。
